Arterially directed therapies for hepatocellular carcinoma

American Journal of Roentgenology

Volumn 197, Issue 4, 2011, Pages

  Shah, Rajesh P ^a   Brown, Karen T ^a   Sofocleous, Constantinos T ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Arterial directed therapy; Chemoembolization; Hepatocellular carcinoma; Particle embolization; Radioembolization

Indexed keywords

ANOREXIA; ARTIFICIAL EMBOLISM; BILOMA; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED TOMOGRAPHY; DRUG DELIVERY SYSTEM; DRUG ELUTING BEAD; FATIGUE; FEVER; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; INTERMETHOD COMPARISON; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TOXICITY; LUNG EDEMA; LUNG EMBOLISM; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAIN; PANCREATITIS; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION INJURY; RADIOEMBOLIZATION; REVIEW; SOCIAL CARE; SUPPORT GROUP; THERAPY EFFECT; VOMITING; WEAKNESS;

ARTERIES; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; MICROSPHERES; NEOPLASM STAGING; PATIENT SELECTION;

EID: 80053263681     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.7554     Document Type: Review

References (88)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90
2. American Cancer Society. Cancer facts and figures 2010. Atlanta, Georgia: American Cancer Society, 2010
3. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27:1485-1491
4. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132:2557-2576 (Pubitemid 46890874)
5. Hsu CY, Hsia CY, Huang YH, et al. Selecting an optimal staging system for hepatocellular carcinoma. Cancer 2010; 116:3006-3014
6. Thomas MB, Jaffe D, Choti MM, et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28:3994-4005
7. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-338
8. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699
9. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390
10. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic-artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148:397-401 (Pubitemid 13073577)
11. Brown DB, Fundakowski CE, Lisker-Melman M, et al. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol 2004; 15:1209-1218 (Pubitemid 39487850)
12. Kothary N, Weintraub JL, Susman J, Rundback JH. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 2007; 18:1517-1526 (Pubitemid 350151875)
13. Carr BI, Irish W, Federle MP. Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis. Hepatogastroenterology 2010; 57:1375-1381
14. Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology 2011; 258:627-634
15. Deodhar A, Covey AM, Thornton R, et al. Safety and efficacy of transcatheter arterial embolization with particles only in the treatment of hepatocellular carcinoma with portal vein thrombus. J Interventional Oncology 2010; 3:3-11
16. Thornton RH, Covey A, Petre EN, et al. A comparison of outcomes from treating hepatocellular carcinoma by hepatic artery embolization in patients younger or older than 70 years. Cancer 2009; 115:5000-5006
17. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediatestage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37:212-220
18. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. Int J Radiat Oncol Biol Phys 2007; 68:13-23 (Pubitemid 46589861)
19. Dunfee BL, Riaz A, Lewandowski RJ, et al. Yttrium-90 radioembolization for liver malignancies: prognostic factors associated with survival. J Vasc Interv Radiol 2010; 21:90-95
20. Chung JW, Park JH, Han JK, Choi BI, Kim TK, Han MC. Transcatheter oily chemoembolization of the inferior phrenic artery in hepatocellular carcinoma: the safety and potential therapeutic role. J Vasc Interv Radiol 1998; 9:495-500 (Pubitemid 28255573)
21. Park SI, Yun Lee D, Yoon Won J, Tae Lee J. Extrahepatic collateral supply of hepatocellular carcinoma by the intercostal arteries. J Vasc Interv Radiol 2003; 14:461-468 (Pubitemid 36423167)
22. Kim H-C, Chung JW, Choi SH, et al. Hepatocellular carcinoma with internal mammary artery supply: feasibility and efficacy of transarterial chemoembolization and factors affecting patient prognosis. J Vasc Interv Radiol 2007; 18:611-619 (Pubitemid 46671576)
23. Kakeda S, Korogi Y, Ohnari N, et al. Usefulness of cone-beam volume CT with flat panel detectors in conjunction with catheter angiography for transcatheter arterial embolization. J Vasc Interv Radiol 2007; 18:1508-1516 (Pubitemid 350151872)
24. Tognolini A, Louie JD, Hwang GL, Hofmann LV, Sze DY, Kothary N. Utility of C-arm CT in patients with hepatocellular carcinoma undergoing transhepatic arterial chemoembolization. J Vasc Interv Radiol 2010; 21:339-347
25. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30:6-25 (Pubitemid 44900485)
26. Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical-trial for the treatment of hepatocellular-carcinoma: a comparison of Lipiodol-transcatheter arterial embolization with and without adriamycin (1st cooperative study). Cancer Chemother Pharmacol 1992; 31:S1-S6
27. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular-carcinoma: a randomized controlled-study. Cancer 1994; 74:2449-2453
28. Kawai S, Tani M, Okamura J, et al. Prospective and randomized trial of Lipiodol-transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: a comparison of epirubicin and doxorubicin (second cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Semin Oncol 1997; 24(2 suppl 6):S638-S645 (Pubitemid 27209105)
29. Sahara S, Kawai N, Sato M, et al. Prospective comparison of transcatheter arterial chemoembolization with Lipiodol-epirubicin and Lipiodolcisplatin for treatment of recurrent hepatocellular carcinoma. Jpn J Radiol 2010; 28:362-368
30. Kan Z, McCuskey PA, Wright KC, Wallace S. Role of Kupffer cells in iodized oil embolization. Invest Radiol 1994; 29:990-993
31. Raoul JL, Heresbach D, Bretagne JF, et al. Chemoembolization of hepatocellular carcinomas: a study of the biodistribution and pharmacokinetics of doxorubicin. Cancer 1992; 70:585-590
32. Brown DB, Pilgram TK, Darcy MD, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005; 16:1661-1666
33. Dharancy S, Boitard J, Decaens T, et al. Comparison of two techniques of transarterial chemoembolization before liver transplantation for hepatocellular carcinoma: a case-control study. Liver Transpl 2007; 13:665-671
34. Golfieri R, Cappelli A, Cucchetti A, et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas. Hepatology 2011; 53:1580-1589
35. Murakami R, Yoshimatsu S, Yamashita Y, Sagara K, Arakawa A, Takahashi M. Transcatheter hepatic subsegmental arterial chemoembolization therapy using iodized oil for small hepatocellular carcinomas: correlation between Lipiodol accumulation pattern and local recurrence. Acta Radiol 1994; 35:576-580
36. Bellot G, Garcia-Medina R, Gounon P, et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 2009; 29:2570-2581
37. Papandreou I, Krishna C, Kaper F, Cai DL, Giaccia AJ, Denko NC. Anoxia is necessary for tumor cell toxicity caused by a low-oxygen environment. Cancer Res 2005; 65:3171-3178 (Pubitemid 40524598)
38. Derdeyn CP, Graves VB, Salamat MS, Rappe A. Collagen-coated acrylic microspheres for embolotherapy: in vivo and in vitro characteristics. AJNR 1997; 18:647-653 (Pubitemid 27175959)
39. Bilbao JI, De Luis E, García de Jalón JA, et al. Comparative study of four different spherical embolic particles in an animal model: a morphologic and histologic evaluation. J Vasc Interv Radiol 2008; 19:1625-1638
40. Stampfl S, Bellemann N, Stampfl U, et al. Arterial distribution characteristics of embozene particles and comparison with other spherical embolic agents in the porcine acute embolization model. J Vasc Interv Radiol 2009; 20:1597-1607
41. Erinjeri JP, Salhab HM, Covey AM, Getrajdman GI, Brown KT. Arterial patency after repeated hepatic artery bland particle embolization. J Vasc Interv Radiol 2010; 21:522-526
42. Wang X, Erinjeri JP, Brown KT, et al. Abstract no. 176: contrast retention on immediate post-procedure CT following particle embolization of liver neoplasms correlates with treatment response. J Vasc Interv Radiol 2011; 22:S76
43. Lee K, Liapi E, Vossen J, et al. Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol 2008; 19:1490-1496
44. Namur J, Wassef M, Millot J-M, Lewis AL, Manfait M, Laurent A. Drug-eluting beads for liver embolization: concentration of doxorubicin in tissue and in beads in a pig model. J Vasc Interv Radiol 2010; 21:259-267
45. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind J-FH. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006; 12:2563-2567
46. Lee K-H, Liapi EA, Cornell C, et al. Doxorubicinloaded QuadraSphere microspheres: plasma pharmacokinetics and intratumoral drug concentration in an animal model of liver cancer. Cardiovasc Intervent Radiol 2010; 33:576-582
47. Meade VM, Burton MA, Gray BN, Self GW. Distribution of different sized microspheres in experimental hepatic tumours. Eur J Cancer Clin Oncol 1987; 23:37-41 (Pubitemid 17228036)
48. SIRTex Medical. SIR-Spheres microspheres training program: physicians and institutions. SIRTex Medical Website. www.sirtex.com/files/TRN-US-0320for20US1. pdf. Accessed July 29, 2011
49. Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006; 17: 1251-1278 (Pubitemid 44259009)
50. 90Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol 2007; 30:571-592
51. Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT. Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 patients. Radiology 2002; 224: 542-547 (Pubitemid 34809139)
52. Kim W, Clark TWI, Baum RA, Soulen MC. Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12:965-968 (Pubitemid 32756867)
53. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33:532-540
54. Atassi B, Bangash AK, Bahram A, et al. Multimodality imaging following Y-90 radioembolization: a comprehensive review and pictorial essay. RadioGraphics 2008; 28:81-99
55. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94:572-586 (Pubitemid 44851918)
56. Deng J, Miller FH, Rhee TK, et al. Diffusionweighted MR imaging for determination of hepatocellular carcinoma response to yttrium-90 radioembolization. J Vasc Interv Radiol 2006; 17:1195-1200 (Pubitemid 44318703)
57. Keppke AL, Salem R, Reddy D, et al. Imaging of hepatocellular carcinoma after treatment with yttrium-90 microspheres. AJR 2007; 188:768-775
58. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216 (Pubitemid 30099779)
59. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247
60. World Health Organization (WHO). WHO handbook for reporting results of cancer treatment: publication no. 48. Geneva, Switzerland: World Health Organization, 1979
61. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001; 35:421-430 (Pubitemid 32844200)
62. Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA 2010; 303:1062-1069
63. Riaz A, Lewandowski RJ, Kulik L, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization. Cardiovasc Intervent Radiol 2010; 33:1143-1152
64. Patel NH, Hahn D, Rapp S, Bergan K, Coldwell DM. Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol 2000; 11:453-460 (Pubitemid 30214840)
65. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol 2001; 12:321-326 (Pubitemid 32217030)
66. Sakamoto I, Aso N, Nagaoki K, et al. Complications associated with transcatheter arterial embolization for hepatic tumors. RadioGraphics 1998; 18:605-619 (Pubitemid 128467047)
67. Brown DB, Cardella JF, Sacks D, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 2006; 17:225-232
68. Chung JW, Park JH, Im JG, Han JK, Han MC. Pulmonary oil embolism after transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1993; 187:689-693
69. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41-52
70. Brown KT. Fatal pulmonary complications after arterial embolization with 40-120-mu m tris-acryl gelatin microspheres. J Vasc Interv Radiol 2004; 15:197-200 (Pubitemid 38248922)
71. Bonomo G, Pedicini V, Monfardini L, et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly sizecalibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol 2009; 33:552-559
72. Maluccio M, Covey A, Porat L, et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2008; 19:862-869
73. Riaz A, Lewandowski RJ, Kulik LM, et al. Complications following radioembolization with yttrium-90 microspheres: a comprehensive literature review. J Vasc Interv Radiol 2009; 20: 1121-1130
74. Sangro B, Gil-Alzugaray B, Rodriguez J, et al. Liver disease induced by radioembolization of liver tumors. Cancer 2008; 112:1538-1546
75. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739 (Pubitemid 34607087)
76. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial Lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171 (Pubitemid 34454013)
77. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224:47-54 (Pubitemid 34680374)
78. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37:429-442 (Pubitemid 36152543)
79. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46:474-481 (Pubitemid 46201723)
80. Poon RTP, Tso WK, Pang RWC, et al. A phase I/ II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5:1100-1108
81. Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2009; 33:541-551
82. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138:52-64
83. Geschwind JFH, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127:S194-S205 (Pubitemid 39423388)
84. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2011; 34:422-431
85. Child C, Turcotte J. Surgery and portal hypertension. In: The liver and portal hypertension. Philadelphia, PA: Saunders, 1964:50-64
86. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56:918-928 (Pubitemid 15228292)
87. [No authors listed]. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000; 31:840-845
88. Kudo M, Chung H, Haji S, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: The JIS score compared with the CLIP score. Hepatology 2004; 40:1396-1405 (Pubitemid 39657014)